Discovered as the first tumor phagocytosis checkpoint at the end of the 21st century, blocking the CD47-SIRPα axis or combining it with other therapies has been proven to be a promising treatment strategy in cancer immunotherapy. This evidence concerns the gene SIRPA and neoplasm.